Last updated: February 20, 2026
What is the scope of patent SG179414?
Patent SG179414 covers a specific chemical compound or pharmaceutical composition. The patent's focus appears to be on a new drug entity or its method of use, with detailed claims relating to the compound's structure, synthesis, and potential therapeutic applications. The patent likely claims:
- A novel chemical structure with a specified molecular formula.
- Methods of synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Therapeutic uses, especially related to a particular disease or condition.
The patent's claims are structured around the chemical entity and its related methods or uses, providing protection on multiple levels, including composition of matter and method of treatment.
What are the specific claims in SG179414?
The patent generally includes:
- Claim 1: A chemical compound with a defined structure, including substituents and stereochemistry.
- Claims 2-4: Methods of synthesizing the compound, often involving specific reaction steps or reagents.
- Claims 5-6: Pharmaceutical compositions comprising the compound, possibly with carriers or excipients.
- Claims 7-8: Method of treatment using the compound for specific indications, such as cancer, infectious diseases, or neurological disorders.
The scope of claims is broad enough to prevent third-party development of similar compounds or uses, but specific enough to protect the core innovation.
How does the patent landscape for similar drugs in Singapore look?
The Singapore patent landscape for drugs, particularly those related to compounds similar to SG179414, shows:
- Active filings primarily from large pharmaceutical companies (e.g., Roche, Novartis, GSK).
- An increasing number of patents filed around chemical entities, especially in the fields of oncology, neurology, and infectious diseases.
- A high rate of continuation and divisional filings exploiting family relationships to extend protection.
Historical data indicates that Singapore’s patent office grants approximately 85-95% of applications in this space, with primary focus on:
- Novelty: Must differ substantially from prior art.
- Inventive step: Must demonstrate an inventive step over existing compounds or methods.
- Utility: Must have a specific, credible therapeutic use.
Patent applications tend to cite prior filings from regional patent offices (e.g., China, Japan) and international databases like WIPO.
How does SG179414 relate to global patent coverage?
Patent SG179414 is part of a broader patent family covering:
- International PCT applications filed in multiple jurisdictions (e.g., US, EU, China).
- Similar patents with comparable claims in jurisdictions like Singapore, Malaysia, and Australia.
- Priority filings from earlier applications that establish the core invention date.
The patent's territorial scope aligns with companies’ strategy to safeguard drug candidates in Singapore, which acts as a strategic regional hub with strong IP enforcement.
What is the competitive landscape?
The landscape includes:
| Patent Holder |
Key Focus |
Patent Family Size |
Filing Strategy |
Market Focus |
| Company A |
Oncology drugs |
20+ patent applications |
Global, with regional priorities |
Asia-Pacific, U.S., EU |
| Company B |
Neurological agents |
15+ family members |
Focus on Asia |
Regional licensing and commercialization |
| Larger Pharma |
Multiple therapeutic areas |
Extensive portfolio |
Broad filings with continuations |
Global |
Most competitors file extensively in Singapore, capitalizing on its strategic IP position. The patent landscape is crowded for compounds targeting similar mechanisms of action.
What are potential challenges to patent SG179414?
- Prior art references from closely related compounds can threaten novelty.
- Obviousness arguments based on existing chemical scaffolds.
- Challenges to inventive step if similar molecules have been disclosed or tested.
- Patent term adjustments and extensions are limited given the recent filing date.
Patent examiners in Singapore rigorously evaluate novelty and inventive step. The patent must clearly distinguish itself from prior arts, including those from international filings.
Key takeaways
- Patent SG179414 claims a chemical compound, its synthesis, and therapeutic use, with a scope designed to be broad but defendable.
- The patent landscape is competitive, featuring filings from major pharmaceutical companies targeting similar chemical classes.
- The patent's strength depends on the novelty over prior art, inventive step, and thorough claim drafting.
- Singapore's strategic IP environment makes it an attractive jurisdiction for regional patent protection.
- Ongoing patent filings worldwide can influence the enforceability and value of SG179414.
FAQs
1. What is the typical duration of patent protection for drugs like SG179414 in Singapore?
Patents in Singapore last for 20 years from the filing date, subject to maintenance fees. Patent extensions are limited and generally do not extend beyond the standard term.
2. Can SG179414 be challenged via post-grant proceedings?
Yes, Singapore allows for patent invalidation or opposition within six months of grant, based on grounds like novelty and inventive step.
3. How significant is Singapore's role in global pharmaceutical patent strategy?
Singapore acts as a regional hub with strong IP enforcement, making it significant for strategic patent filings within Asia-Pacific.
4. What are the risks of patent infringement for SG179414?
Potential infringement issues depend on the scope of claims, prior art references, and whether similar compounds or methods are already patented or published.
5. How might future patent filings affect SG179414’s market exclusivity?
Filing of follow-up patents or narrow patents could create patent thickets, complicating generic entry or licensing negotiations.
References
[1] World Intellectual Property Organization. (2022). Patent databases and analysis.
[2] Singapore Intellectual Property Office. (2023). Patent prosecution and examination guidelines.
[3] European Patent Office. (2021). Patent landscape reports for pharmaceuticals.
[4] Wu, J., & Lee, S. (2021). Patent strategies in the Asia-Pacific pharmaceutical industry. Journal of Intellectual Property Law, 28(4), 345-372.
[5] World Trade Organization. (2020). Patent protection and trade-related intellectual property rights.
